2024-03-29, Fri.

Top Stories       Business       Culture & Life       Science & Technology       World

Lecture

Notification

 

NEWS > Business


Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Research collaboration covers multiple antibody research programs
Date: 2021-09-10

SOUTH SAN FRANCISCO, CALIF. & INGELHEIM, GERMANY-- September 10, 2021 -- Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim.

“Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. Wood, Ph.D., Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “We look forward to working with Twist on molecular targets in a broad range of disease areas,” added Wood.

Under the terms of the agreement, Twist Biopharma, a division of Twist, will utilize its “Library of Libraries,” a panel of synthetic antibody phage display libraries derived only from sequences that exist in the human body, to identify potential therapeutic antibody candidates. Twist and Boehringer Ingelheim will work together to validate and optimize any resulting new antibody candidates, which could be researched against a range of therapeutic areas. Boehringer Ingelheim retains exclusive worldwide rights to develop and commercialize any therapeutic antibodies discovered as part of the collaboration.

Twist will receive an upfront payment for each program entry. In addition, Twist has the potential to earn up to a total of $710 million in success-based clinical, regulatory and commercial milestone payments for the multiple target discovery programs.

“This discovery collaboration with Boehringer Ingelheim covering numerous targets truly illustrates the power of our antibody libraries. We have the ability to generate precise antibodies to a diverse range of targets, which together with Boehringer Ingelheim’s strength in drug development capabilities, could mean multiple new, more personalized treatments in the future for patients,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist.



 to the Top List of News

Clean Water and Sustainable Lifestyle: LG¡¯s Mindful Innovations
Everen Declares $350 Million Dividend and Announces Retirement of Chief Executive Officer in 2025
GCT Semiconductor Becomes a Publicly Traded Company After Completing Business Combination with Concord Acquisition Corp III, Will Commence Trading on
From Ransomware to Pig Butchering, Visa Report Shows Top Scams Impacting Consumers and Businesses Globally
Lifezone Metals Signs Binding Subscription Agreement for US$50 Million of Unsecured Convertible Debentures with Consortium of Marquee Mining Investors
Kasikorn Securities Selects ICE for Enhanced Portfolio Analytics and Risk Management for Derivatives
Faraday Partnered with SONIX to Create a New Product Featuring Its SONOS eFlash Solution

 

Merck Invests More than ¢æ 300 Million in New Life Science Production ...
MUMBAI, INDIA--(Business Wire / Korea Newswire)--India¡¯s leading law ...
ZAPI GROUP Showcases New Solutions in Material Automation at LogiMAT 2...
2024 Thales Data Threat Report Reveals Rise in Ransomware Attacks, as ...
AngloGold Ashanti Releases Preliminary Unaudited Condensed Consolidate...
Visa Foundation Helps To Uplift More Than Four Million SMBs
Andersen Global Bolsters Presence in China
Lifezone Metals Announces Receipt of Licence from Government of Tanzan...
[On the Job] Breaking Boundaries: Exploring Human-Centered Innovation ...
Black & Veatch Offering Insights to High-Level Presidential Trade and ...

 

 

60, Gamasanro 27gil, Guro-gu, Seoul, Korea, e-mail: news@newsji.com

Copyright, NEWSJI NETWORK.